All In Biotech

Drug Trial Radar · NCT05138887

A Study for Assessing the Efficacy and Safety of BH4 in Radiation Enteritis

Clinical Professor

Last checked: Nov 20, 2026Latest source record: Mar 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 366 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

366

Planned (sponsor's estimate)

Start

Mar 1, 2022

Primary completion

Oct 1, 2023

Study completion Mar 1, 2024

Sponsor

Lead sponsor
West China Second University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This present study envisaged a single-center, prospective, open-label, placebo and randomized controlled phase II clinical study to assess the efficacy and Safety of Tetrahydrobiopterin in Treating Radiation Enteritis in Gynecological Cancer Patients.

Conditions

  • Radiation Enteritis

Interventions

  • TetrahydrobiopterinDrug

    The experimental group1 was administered BH4 orally with a dose of 2 mg/kg.d, once per day, and the experimental group 2 was administered BH4 orally witha dose of 5 mg/kg.d, two times a day (If the drug dose is within the range of 151-250mg, the drug dose is 200mg) or three times a day (If the drug dose is within the range of 251-350mg, the drug dose is 300mg). The oral administration of pills was started on the same day of the first radiation treatment, and ended three months after the treatment ended.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. acute radiation-induced proctitis (ARP) incidenceTime frame: up to 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • est China Second Hospital of Sichuan University

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.